Teza Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Teza Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,018	Closed	-$1.26M	–	777
2024 Q1	$1.26M	Buy	3,018 +2,010	+199%	+$850K	0.17%	166
2023 Q4	$410K	Sell	1,008 -3,172	-76%	-$1.17M	0.07%	338
2023 Q3	$1.45M	Buy	+4,180	New	+$1.46M	0.24%	123
2022 Q1	–	Sell	-1,208	Closed	-$265K	–	552
2021 Q4	$265K	Sell	1,208 -4,201	-78%	-$817K	0.07%	347
2021 Q3	$981K	Buy	+5,409	New	+$1.06M	0.47%	58
2021 Q2	–	Sell	-2,280	Closed	-$490K	–	706
2021 Q1	$490K	Buy	+2,280	New	+$501K	0.1%	281
2018 Q2	–	Sell	-4,880	Closed	-$795K	–	584
2018 Q1	$795K	Buy	4,880 +1,692	+53%	+$276K	0.19%	214
2017 Q4	$478K	Buy	+3,188	New	+$472K	0.29%	150

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Teza Capital Management's VRTX Position: Q2 2024 in Review

Teza Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 3,018 shares — an estimated $1.26M sold.

Teza Capital Management first reported a position in VRTX in Q4 2017 and held it in 8 quarters. The position peaked at $1.45M in Q3 2023. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Teza Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Teza Capital Management sold 3,018 Vertex Pharmaceuticals shares in Q2 2024, an estimated $1.26M.
Teza Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Teza Capital Management's Vertex Pharmaceuticals position peaked at $1.45M in Q3 2023.
1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Teza Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.